Literature DB >> 21833558

Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

Eduard García-Cruz1, Jorge Huguet, Marta Piqueras, Meritxell Pérez Márquez, Lluís Peri, Laura Izquierdo, Agustín Franco, Ricardo Alvarez-Vijande, María José Ribal, Antonio Alcaraz.   

Abstract

INTRODUCTION: Relationship between prostate cancer (PCa) and testosterone (T) is controversial. Conflicting evidence has been published about T levels and development of PCa. AIM: (1) To determine the relationship between hormone levels and the diagnosis of PCa. (2) To specifically focus on the relationship between PCa and T in men classified as biochemically hypogonadal.
MATERIALS AND METHODS: Prospective analysis of 1,000 transrectal ultrasound guided prostate biopsies (5 + 5 cores biopsies) between September 2007 and January 2010 in one center. Indication for prostate biopsy was suspicion of PCa on the basis of elevated prostate-specific antigen (PSA) and/or digital rectal examination (DRE). Serum testosterone and sex hormones binding globulin (SHBG) were determined in these patients. Of 557 men, the data were sufficient for further analysis. Age, body mass index (BMI), smoking/drinking habits, PSA, free PSA, PSA density, prostate volume, number of previous biopsies, DRE, and hormone levels were prospectively recorded.
RESULTS: No relationship was found between T and PCa (449 ± 167 ng/dL in PCa versus 437 ± 169 ng/dL in non-PCa). SHBG was significantly higher in patients with PCa (51 ± 27 ng/dL in PCa vs. 44 ± 18 ng/dL in non-PCa). In hypogonadal men, T levels correlated with the PCa (235 ± 95 ng/dL in men with PCa versus 270 ± 58 ng/dL in men without PCa, P = 0.004).
CONCLUSIONS: T levels were comparable in men with and without PCa, but SHBG levels were significantly higher in men with PCa. In men with low T, the men with PCa had a lower serum T levels and a lower prostate volume than the men without PCa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833558     DOI: 10.1007/s00345-011-0741-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  24 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

Review 2.  Risks of testosterone-replacement therapy and recommendations for monitoring.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

3.  Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship.

Authors:  Abraham Morgentaler
Journal:  Eur Urol       Date:  2007-04-09       Impact factor: 20.096

4.  The Effect of Castration on Benign Hypertrophy of the Prostate in Man.

Authors:  Charles Huggins; Roland A Stevens
Journal:  J Urol       Date:  2016-12-21       Impact factor: 7.450

5.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

6.  Occult prostate cancer in men with low serum testosterone levels.

Authors:  A Morgentaler; C O Bruning; W C DeWolf
Journal:  JAMA       Date:  1996-12-18       Impact factor: 56.272

7.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Olga M Calof; Atam B Singh; Martin L Lee; Anne M Kenny; Randall J Urban; Joyce L Tenover; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-11       Impact factor: 6.053

8.  Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study.

Authors:  A Gray; H A Feldman; J B McKinlay; C Longcope
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

9.  Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer.

Authors:  M Ribeiro; P Ruff; G Falkson
Journal:  Am J Clin Oncol       Date:  1997-12       Impact factor: 2.339

10.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Authors:  Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

View more
  3 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.

Authors:  Lucio Dell'Atti; Andrea B Galosi
Journal:  Asian J Androl       Date:  2018 Jan-Feb       Impact factor: 3.285

3.  Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result.

Authors:  Alexandros Fiamegos; John Varkarakis; Michael Kontraros; Andreas Karagiannis; Michael Chrisofos; Dimitrios Barbalias; Charalampos Deliveliotis
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.